Back to Journals » Drug Design, Development and Therapy » Volume 4

Original Research

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

       
Total article views   HTML views PDF downloads Totals
19,336 Dovepress* 17,477+ 2,087 19,564
PubMed Central* 1,859 687 2,546
Totals 19,336 2,774 22,110
*Since 15 November 2010
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
8 0 0 0 0 8

View citations on PubMed Central and Google Scholar